Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 8;16(6):1163-1169.
doi: 10.1021/acsmedchemlett.5c00204. eCollection 2025 Jun 12.

Discovery and Optimization of 6‑Azaindole URAT1 Inhibitors to Address Kidney and Liver Related Toxicities

Qihui Jin  1 , Tom Y-H Wu  1
Affiliations

Discovery and Optimization of 6‑Azaindole URAT1 Inhibitors to Address Kidney and Liver Related Toxicities

Qihui Jin et al. ACS Med Chem Lett. .

Abstract

Gout is a metabolic disorder characterized by excessive uric acid accumulation, often managed by uric acid transporter 1 (URAT1) inhibitors. However, existing URAT1 inhibitors such as lesinurad and benzbromarone present significant kidney and liver toxicity risks, respectively. To address these limitations, we designed and optimized a novel series of 6-azaindole URAT1 inhibitors, culminating in the lead candidate 22k. 22k demonstrated a favorable pharmacokinetic (PK) profile with a lower peak-to-trough ratio compared to lesinurad, suggesting slower renal clearance and a reduced risk of uric acid microcrystallization in the kidneys. Additionally, 22k exhibited no glutathione (GSH) trapping, unlike benzbromarone, indicating reduced risk of reactive metabolites formation and a lower potential for idiosyncratic liver toxicity. These findings highlight 22k as a promising next-generation URAT1 inhibitor with improved safety profile, warranting further investigations.

Keywords: Azaindole; Benzbromarone; Gout; Lesinurad; URAT1.

PubMed Disclaimer

References

    1. Benn C. L., Dua P., Gurrell R., Loudon P., Pike A., Storer R. I., Vangjeli C.. Physiology of Hyperuricemia and Urate-Lowering Treatments. Front. Med. 2018;5:160. doi: 10.3389/fmed.2018.00160. - DOI - PMC - PubMed
    1. Li X., Liu J., Ma L., Fu P.. Pharmacological urate-lowering approaches in chronic kidney disease. Eur. J. Med. Chem. 2019;166:186–196. doi: 10.1016/j.ejmech.2019.01.043. - DOI - PubMed
    1. Strilchuk L., Fogacci F., Cicero A. F.. Safety and tolerability of available urate-lowering drugs: a critical review. Expert Opin. Drug Saf. 2019;18:261–271. doi: 10.1080/14740338.2019.1594771. - DOI - PubMed
    1. Perez-Ruiz F., Dalbeth N.. Combination urate-lowering therapy in the treatment of gout: What is the evidence? Semin. Arthritis Rheum. 2019;48:658–668. doi: 10.1016/j.semarthrit.2018.06.004. - DOI - PubMed
    1. Tausche A. K., Alten R., Dalbeth N., Kopicko J., Fung M., Adler S., Bhakta N., Storgard C., Baumgartner S., Saag K.. Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study. Rheumatology. 2017;56:2170–2178. doi: 10.1093/rheumatology/kex350. - DOI - PubMed

LinkOut - more resources